Gilead Sciences has secured emergency use authorisation (EUA) from the US Food and Drug Administration (FDA) for remdesivir to treat Covid-19 infection.
The authorisation is set to allow broader access to remdesivir for treating hospitalised patients with severe Covid-19 across the US.
Gilead will work with the government to allocate the currently limited supply of the drug. Gilead Sciences chairman and CEO Daniel O’Day said: “This EUA opens the way for us to provide emergency use of remdesivir to more patients with severe symptoms of Covid-19. “We will continue to work with partners across the globe to increase our supply of remdesivir while advancing our ongoing clinical trials to supplement our understanding of the drug’s profile.”